MX383201B - Formulación de combinación farmacéutica. - Google Patents

Formulación de combinación farmacéutica.

Info

Publication number
MX383201B
MX383201B MX2018007976A MX2018007976A MX383201B MX 383201 B MX383201 B MX 383201B MX 2018007976 A MX2018007976 A MX 2018007976A MX 2018007976 A MX2018007976 A MX 2018007976A MX 383201 B MX383201 B MX 383201B
Authority
MX
Mexico
Prior art keywords
pharmaceutical combination
combination formulation
tablet
relates
present
Prior art date
Application number
MX2018007976A
Other languages
English (en)
Other versions
MX2018007976A (es
Inventor
Ah- Reum Chae
Hyun- Woo JUNG
Lee Jae-Young
Jei- Man Ryu
Kyoung- Hwan KANG
Soo- Won Kim
Woo- Ile PARK
Woo- Kyung KIM
Original Assignee
Shin Poong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58543052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX383201(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shin Poong Pharmaceutical Co Ltd filed Critical Shin Poong Pharmaceutical Co Ltd
Publication of MX2018007976A publication Critical patent/MX2018007976A/es
Publication of MX383201B publication Critical patent/MX383201B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una tableta que comprende candesartán o candesartán cilexetilo y amlodipina o su sal farmacéuticamente aceptable como ingredientes activos, usando la tableta un solubilizante particular para mejorar significativamente las propiedades de estabilidad y disolución de los ingredientes activos. Además, la presente invención se refiere a un método para preparar la tableta.
MX2018007976A 2015-12-28 2016-12-28 Formulación de combinación farmacéutica. MX383201B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150187679A KR101710441B1 (ko) 2015-12-28 2015-12-28 안정성 및 용출성이 향상된 정제
PCT/KR2016/015439 WO2017116150A1 (ko) 2015-12-28 2016-12-28 약제학적 복합제제

Publications (2)

Publication Number Publication Date
MX2018007976A MX2018007976A (es) 2019-03-28
MX383201B true MX383201B (es) 2025-03-13

Family

ID=58543052

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007976A MX383201B (es) 2015-12-28 2016-12-28 Formulación de combinación farmacéutica.

Country Status (14)

Country Link
US (1) US20190015339A1 (es)
EP (1) EP3398589B1 (es)
JP (1) JP6797924B2 (es)
KR (1) KR101710441B1 (es)
CN (1) CN108472257B (es)
CA (1) CA3009468C (es)
CO (1) CO2018007821A2 (es)
ES (1) ES2868602T3 (es)
MX (1) MX383201B (es)
MY (1) MY194591A (es)
PE (1) PE20181374A1 (es)
PH (1) PH12018501392A1 (es)
RU (1) RU2736942C2 (es)
WO (1) WO2017116150A1 (es)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
ITMI20012366A1 (it) * 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
WO2005084648A1 (en) 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Pharmaceutical compositions comprising candesartan cilexetil
EP1814527B2 (en) * 2004-11-05 2020-11-18 Boehringer Ingelheim International GmbH Bilayer tablet comprising telmisartan and amlodipine
GB0600709D0 (en) 2006-01-13 2006-02-22 Portela & Ca Sa Drug combinations
CN101528224A (zh) * 2006-09-05 2009-09-09 阿斯利康(瑞典)有限公司 包含坎地沙坦西酯的药用组合物
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
KR101247583B1 (ko) * 2006-12-08 2013-03-26 한미사이언스 주식회사 암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물
SI2165702T1 (sl) * 2008-09-17 2012-05-31 Helm Ag Stabilni in z lahkoto raztopljeni sestavki kandesartan cileksetila pripravljeni z vlažno granulacijo
KR20100048137A (ko) * 2008-10-30 2010-05-11 현대약품 주식회사 혈압 강하용 약학 조성물
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
KR20090065510A (ko) * 2009-03-13 2009-06-22 다이이찌 산쿄 가부시키가이샤 올메사탄 메독소밀 및 암로디핀의 고형 투여 제형
RU2539382C2 (ru) 2009-06-26 2015-01-20 Тейдзин Фарма Лимитед Лекарственное средство для лечения гипертензии или повышенного кровяного давления
KR101171375B1 (ko) * 2010-01-20 2012-08-13 한올바이오파마주식회사 난용성 약물을 함유하는 경구 제형
CN101966181A (zh) * 2010-07-08 2011-02-09 王丽燕 包含坎地沙坦和氨氯地平的口服固体制剂及其新应用
KR101168136B1 (ko) * 2011-08-08 2012-07-24 보령제약 주식회사 혈압 강하용 약제학적 조성물
CN102349902B (zh) * 2011-08-19 2013-05-01 海南锦瑞制药股份有限公司 一种含有左旋氨氯地平和坎地沙坦酯的药物组合物及其制备方法
CN102688236B (zh) * 2012-06-06 2014-03-26 石药集团中诺药业（石家庄）有限公司 一种坎地沙坦酯氨氯地平片剂组合物及其制备方法
KR101302883B1 (ko) * 2012-07-23 2013-09-05 삼일제약주식회사 텔미사르탄을 유효성분으로 포함하는 안정성이 증가된 약제학적 조성물 및 그 제조방법
MX351059B (es) * 2012-08-17 2017-09-29 Laboratorios Senosiain S A De C V Star Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion.
PL236001B1 (pl) * 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję

Also Published As

Publication number Publication date
CN108472257A (zh) 2018-08-31
RU2018126354A (ru) 2020-01-31
CO2018007821A2 (es) 2018-08-10
JP2019500392A (ja) 2019-01-10
CA3009468A1 (en) 2017-07-06
MX2018007976A (es) 2019-03-28
JP6797924B2 (ja) 2020-12-09
US20190015339A1 (en) 2019-01-17
EP3398589B1 (en) 2021-01-27
EP3398589A4 (en) 2019-08-28
EP3398589A1 (en) 2018-11-07
PE20181374A1 (es) 2018-08-28
KR101710441B1 (ko) 2017-02-28
BR112018013121A2 (pt) 2018-12-11
CA3009468C (en) 2024-06-25
CN108472257B (zh) 2020-12-04
PH12018501392A1 (en) 2019-02-27
WO2017116150A1 (ko) 2017-07-06
MY194591A (en) 2022-12-05
RU2018126354A3 (es) 2020-05-12
RU2736942C2 (ru) 2020-11-23
ES2868602T3 (es) 2021-10-21

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MY187047A (en) Selective pyy compounds and uses thereof
MX391180B (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo
ZA201707096B (en) Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient
MX2017014994A (es) Formulacion solida oral que contiene irinotecano y metodo de preparacion de la misma.
MX2020012989A (es) Agente terapeutico para la fibrosis.
MX2016001422A (es) Composicion farmaceutica de fingolimod.
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
MX383201B (es) Formulación de combinación farmacéutica.
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
ZA201801839B (en) Pharmaceutical composition for preventing and treating liver diseases, containing, as active ingredient, cromolyn or pharmaceutically acceptable salt thereof
PH12016502527B1 (en) Stabilized desmopressin
ZA201803722B (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
PH12020550597A1 (en) Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt
GR1008380B (el) Φαρμακευτικο σκευασμα περιεχον ενα αντιικο παραγοντα και μεθοδος για την παρασκευη αυτου
TH1801003854A (th) ยาเตรียมแบบคอมโพสิตทางเภสัชกรรม
UA97982U (uk) Лікарський засіб седативної дії у вигляді таблеток
IN2015MU00907A (es)
HK1251178A1 (zh) 用於预防由放射疗法引起的皮肤损伤的可乐定和/或可乐定衍生物
PL409699A1 (pl) Kompozycja farmaceutyczna zawierająca nystatynę oraz beta-escynę lub ich dopuszczalne farmaceutycznie sole oraz jej zastosowanie